England’s National Health Service’s faecal immunochemical test (FIT) has reduced referrals for suspected bowel cancer by ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term ...

We compared a noninvasive, multitarget stool DNA test with a fecal immunochemical test (FIT) in persons at average risk for colorectal cancer. The DNA test includes quantitative molecular assays for ...

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

Multitarget stool-based tests are showing promise for colorectal cancer (CRC) screening in average-risk individuals and could edge out the current standard fecal immunochemical test (FIT). These new ...

Please provide your email address to receive an email when new articles are posted on . In a prospective study, researchers enrolled 457 asymptomatic participants (mean age 61.4 years; 75% women) from ...

In DID analysis, the rate of incidence was reduced by 0.34 cases per person-years in the screening group as compared with the historical FIT screening group (rate ratio [RR], 0.08 [95% CI, 0.07 to ...

Screening with fecal immunochemical tests (FITs) lowers the risk of dying from colorectal cancer (CRC), according to a study published online July 19 in JAMA Network Open. Lowering the fecal ...

Commercially available noninvasive screening tests for colorectal cancer - a fecal immunochemical test (FIT) and the multi-target stool DNAtest (mt-sDNA; or Cologuard ®) - are equally effective for ...

Annual fecal immunochemical test-based surveillance could be as effective as colonoscopies in reducing long-term colorectal cancer incidence and mortality, according to a recent study published in ...